Autoimmune hepatitis cannot be cured, but it can be controlled. With standard treatment, roughly 65% to 80% of people achieve remission, meaning the immune system’s attack on the liver slows or stops and liver inflammation returns to normal levels. The distinction matters: remission means the disease is quiet, not gone. Most people need medication for years, and many need it for life.
Why Remission Is Not the Same as a Cure
In autoimmune hepatitis, your immune system mistakenly targets liver cells as if they were foreign invaders. Treatment suppresses that immune response, which allows the liver to heal and inflammation markers to normalize. When blood tests show normal liver enzyme levels and normal immunoglobulin levels, doctors call that biochemical remission. It’s the primary goal of treatment, and it’s achievable for most people.
The problem is what happens when treatment stops. After maintaining remission for at least two years, your doctor may try tapering you off medication to see if remission holds on its own. For most people, it doesn’t. Studies consistently find that about two-thirds of patients relapse within an average of 1.5 years after stopping their drugs. That high relapse rate is the core reason autoimmune hepatitis is classified as a long-term, often lifelong condition rather than something that gets treated and resolved.
A small number of people do stay in remission after discontinuing treatment. But there’s no reliable way to predict who will be in that fortunate minority, which is why doctors approach medication withdrawal cautiously and monitor closely afterward.
What Treatment Looks Like
First-line treatment uses an immune-suppressing steroid to bring the initial flare under control, followed by a second immune-suppressing drug that allows the steroid dose to come down over time. The induction phase typically starts with a relatively high steroid dose that gets tapered over several weeks as liver enzymes improve. Once inflammation is controlled, most people transition to a low maintenance dose of one or both medications.
The side effects of long-term steroids (weight gain, bone thinning, mood changes, elevated blood sugar) are a real concern, and much of the treatment strategy revolves around minimizing steroid exposure. An alternative steroid that acts more locally in the liver produces fewer cosmetic side effects like facial puffiness and acne. It achieves similar remission rates to traditional steroids in people without cirrhosis, though it doesn’t significantly reduce the risk of diabetes or high blood pressure. This option isn’t suitable for people who already have advanced scarring of the liver.
For people who don’t respond to standard therapy, or who can’t tolerate the side effects, second-line options exist, but the first-line combination works for the majority. In one study of 102 treated patients, about 79% achieved biochemical remission, and 52% reached complete remission with near-normal liver tissue on biopsy.
Type 1 vs. Type 2 Autoimmune Hepatitis
Type 1 is far more common and can develop at any age, though it most often appears in women under 40. Type 2 is rarer but more aggressive, typically showing up in childhood. The two types involve different autoantibodies, which helps doctors distinguish them, but treatment follows the same general approach for both. Type 2 tends to be harder to control and more likely to relapse, making long-term medication even more essential for children and adolescents diagnosed with it.
What Happens Without Adequate Treatment
Untreated or poorly controlled autoimmune hepatitis leads to progressive liver scarring (fibrosis), which can advance to cirrhosis and eventually liver failure. A large population-based study found that people with autoimmune hepatitis had roughly twice the mortality risk compared to the general population over 10 years, with a 32% cumulative death rate compared to 14% in matched controls. That elevated risk persisted even beyond 20 years of follow-up. These numbers reflect a mixed population, including people diagnosed late or with incomplete treatment responses, which underscores how important it is to catch and manage the disease early.
When the liver is too damaged to function, a transplant becomes the final option. Transplant outcomes for autoimmune hepatitis are generally good, but the disease can return in the new liver. A meta-analysis of 39 studies found that about 21% of transplant recipients experienced recurrence. The rate was higher in children (31%) and in people who had experienced organ rejection. Even after transplant, ongoing immune suppression and monitoring remain part of life.
Living With Autoimmune Hepatitis Long-Term
For most people, managing autoimmune hepatitis means regular blood tests to track liver enzymes and immunoglobulin levels, periodic check-ins with a liver specialist, and consistent daily medication. The routine becomes familiar over time. When the disease is well controlled, many people feel entirely normal and live without symptoms.
The practical challenges tend to center on medication side effects rather than the disease itself. Weight changes, fatigue, increased infection susceptibility, and bone density loss are the most common long-term concerns. Your doctor will typically monitor bone health and blood sugar alongside liver function, adjusting doses to find the lowest effective amount.
Alcohol is worth mentioning because it independently stresses the liver. Most specialists advise avoiding it entirely or limiting intake significantly. Keeping up with vaccinations matters too, since immune-suppressing medications make you more vulnerable to infections that a healthy immune system would handle easily.
The outlook for autoimmune hepatitis has improved substantially with modern treatment. Most people who respond well to therapy and stay on their maintenance regimen can expect a normal or near-normal quality of life. The disease requires ongoing attention, but it is one that, for the majority of patients, stays firmly in the background once it’s controlled.